Core Viewpoint - The eye health awareness among the Chinese population is increasing, leading to significant growth in the ophthalmic optical instrument industry, which is expected to reach a market size of approximately 4 billion yuan by 2024 [1][15]. Industry Overview - Ophthalmic optical instruments are essential for diagnosing and treating eye diseases, including devices like computer visual field analyzers, automatic refractors, corneal topographers, and fundus cameras [3][4]. - The industry has seen remarkable advancements in technology and product development, with domestic companies enhancing their R&D capabilities and launching high-quality products [1][15]. Market Growth - The market size of China's ophthalmic optical instrument industry has been continuously growing from 2017 to 2023, with projections indicating it will reach around 4 billion yuan in 2024 [1][15]. - The increasing prevalence of age-related eye diseases and lifestyle changes, such as prolonged use of electronic devices, are driving the demand for ophthalmic medical services [13][25]. Industry Chain - The upstream of the ophthalmic optical instrument industry includes suppliers of optical glass and plastic, which are crucial for manufacturing high-quality instruments [9][11]. - The midstream consists of various manufacturers of ophthalmic optical instruments, while the downstream includes hospitals, clinics, and optical shops where these instruments are utilized [9]. Competitive Landscape - The market concentration in the ophthalmic optical instrument industry is relatively high, with a few companies dominating specific product areas like fundus cameras and OCT devices [17][18]. - Key players in the industry include companies like 图拜医疗, 康捷医疗, and 新眼光, which are focusing on high-end product development [17][18]. Policy Environment - Recent policies have been introduced to promote the standardization and regulation of the medical device industry, providing favorable conditions for the growth of the ophthalmic optical instrument sector [4][6]. - The government aims to enhance the quality and safety of medical devices, ensuring a robust regulatory framework by 2035 [6]. Future Trends - The market is expected to further penetrate various healthcare institutions, with handheld devices likely to see widespread adoption in grassroots medical facilities [23]. - The integration of artificial intelligence and big data into ophthalmic optical instruments is becoming mainstream, leading to the development of smart devices that enhance diagnostic capabilities [24][25].

Core Points - The Shanghai Composite Index opened lower and fluctuated, while the CSI All Index for Healthcare Equipment and Services decreased by 0.16%, closing at 14,029.54 points with a trading volume of 15.519 billion yuan [1] - Over the past month, the CSI All Index for Healthcare Equipment and Services has increased by 0.23%, and over the past three months, it has risen by 2.65%, with a year-to-date increase of 2.65% [1] - The index reflects the overall performance of listed companies in the healthcare sector, selected from the CSI All Index, with a base date of December 31, 2004, set at 1,000.0 points [1] Index Composition - The top ten weighted companies in the CSI All Index for Healthcare Equipment and Services are: Mindray Medical (9.28%), Aier Eye Hospital (8.07%), United Imaging (6.7%), Aimeike (3.56%), Huatai Medical (3.16%), New Industry (3.09%), Yuyue Medical (2.83%), Meinian Onehealth (2.33%), Jiuan Medical (2.16%), and Shandong Pharmaceutical Glass (2.05%) [1] - The market share of the index's holdings is 61.07% from the Shenzhen Stock Exchange and 38.93% from the Shanghai Stock Exchange [1] - The index's holdings are entirely composed of the pharmaceutical and healthcare sector, with a 100.00% allocation [1] Index Adjustment and Fund Tracking - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample changes, typically remaining fixed until the next scheduled adjustment, with provisions for temporary adjustments in special circumstances [2] - Public funds tracking the healthcare index include various funds from Southern Fund, Tianhong Fund, and others, specifically designed to follow the CSI All Index for Healthcare Equipment and Services [2]

Core Viewpoint - The China Securities Index for the medical industry has shown a slight decline over the past month, quarter, and year-to-date, indicating a stable but slightly negative trend in the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry is currently at 566.67 points [1]. - Over the past month, the index has decreased by 0.49%, while it has seen a minimal decline of 0.02% over the past three months and year-to-date [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.12%) - Aier Eye Hospital (8.91%) - United Imaging Healthcare (7.39%) - Aimeike (3.93%) - Huatai Medical (3.48%) - New Industries (3.41%) - Yuyue Medical (3.12%) - Shanghai Pharmaceuticals (3.04%) - Meinian Onehealth (2.57%) - Jiuan Medical (2.39%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (57.38%) and the Shanghai Stock Exchange (42.62%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.29% - Medical Consumables: 23.16% - Pharmaceutical Commerce: 15.33% - Medical Services: 14.26% - In Vitro Diagnostics: 12.95% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

问：如今随着医疗技术的飞速发展，近视手术方式日新月异，请介绍一下近视手术的一些技术原理 以及目前常用的一些手术方式类型。 问：安全性是患者较为关心的问题，在近视手术的过程中，爱尔眼科医院会采取哪些措施来全方位地 保障患者的手术安全？ 全流程的管理才能够保证手术的安全。首先是整个团队的配合，从术前开始就要为患者进行全方位 的术前检查，在国内要求激光类手术有11项的必备检查，在爱尔眼科医院会达到20多项，这么多数据汇 总是为了得到一个更完整的患者资料，进行更精准的个性化的设计。 其次是在手术中必须保证设备的安全运行、医护团队的高效配合、检眼师术前测量的精准性，保证 手术医生在手术当中稳定娴熟的技术和患者良好的沟通和配合。 目前近视手术分为"加法手术"和"减法手术"两大类主流的方式。"减法手术"就是激光类手术，又分 为半飞秒手术、全飞秒手术以及表层手术；"加法手术"是ICL植入术，也就是有晶体眼的人工晶状体的 植入手术。 "减法手术"里半飞秒手术也就是LASIK手术，它主要是在角膜基质上做一些切削，然后使角膜曲率 改变，从而获得一个清晰的术后视力；全飞秒手术是做一个非常微创的小切口，然后在角膜基质上做一 个透镜，再 ...

Core Points - The CSI All Share Healthcare Index increased by 0.05%, closing at 8642.42 points with a trading volume of 48.652 billion [1] - Over the past month, the index has risen by 0.21%, while it has decreased by 0.61% over the last three months and increased by 1.70% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI All Share Index, categorized into various levels of industries [1] Index Composition - The top ten weighted stocks in the CSI All Share Healthcare Index include: Heng Rui Medicine (6.67%), WuXi AppTec (5.32%), Mindray Medical (4.71%), Aier Eye Hospital (2.04%), Pian Zai Huang (2.0%), United Imaging Healthcare (1.66%), Yunnan Baiyao (1.6%), Kelun Pharmaceutical (1.27%), New Horizon (1.09%), and Shanghai Raist (1.03%) [1] - The market share of the index's holdings is distributed as follows: Shanghai Stock Exchange 50.92%, Shenzhen Stock Exchange 49.04%, and Beijing Stock Exchange 0.04% [2] - The index is composed entirely of the healthcare sector, with a 100% allocation to healthcare [2] Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to changes in the CSI All Share Index [2] - Special events affecting sample companies may lead to corresponding adjustments in the index, including delisting or corporate actions such as mergers and acquisitions [2]

湖南启元律师事务所 关于爱尔眼科医院集团股份有限公司 2025年第一次临时股东大会的 法律意见书 二零二五年三月二十六日 致：爱尔眼科医院集团股份有限公司 湖南启元律师事务所（以下简称"本所"）接受爱尔眼科医院集团股份有限 公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第一次临时 股东大会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、 出席会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证， 并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）等我国现行法律、法规、规范性文件以及《爱 尔眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）的有关规定 出具本法律意见书。 为出具本法律意见书，本所律师声明如下： （一）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律师的 文件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠， 无隐瞒、虚假或重大遗漏之处。 （二）本所律师遵循了勤勉尽责和诚实 ...

本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 爱尔眼科医院集团股份有限公司（以下简称"公司"）2025 年第一次临时 股东大会采用现场表决与网络投票相结合的方式召开。其中，通过深圳证券交易 所交易系统进行网络投票的时间为：2025 年 3 月 26 日 9:15 至 9:25、9:30 至 11:30， 13:00 至 15:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 3 月 26 日 9:15 至 15:00 期间的任意时间；现场会议于 2025 年 3 月 26 日 14:00 在长沙市芙蓉南路一段 188 号爱尔大厦 B1 层国际会议厅召开。本次股东大会由 公司董事会召集，董事长陈邦先生主持，公司董事、监事、高级管理人员、律师 等相关人士出席了本次会议。会议的召集、召开与表决程序符合法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 股东出席的总体情况： 证券代码：300015 股票简称：爱尔眼 ...

Group 1 - The core viewpoint of the article highlights that Aier Eye Hospital's stock closed down by 1.10%, with a rolling P/E ratio of 34.69 times and a total market capitalization of 125.915 billion yuan [1] - Aier Eye Hospital ranks 25th in the medical services industry, which has an average P/E ratio of 44.19 times and a median of 43.02 times [1] - As of September 30, 2024, Aier Eye Hospital had 372,778 shareholders, an increase of 19,315 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Aier Eye Hospital primarily engages in the diagnosis and treatment of various eye diseases, surgical services, and optical services [1] - The company has hosted significant academic conferences, including the 2019 International Retina Summit and the 2023 World Myopia Conference [1] - For the latest financial performance, Aier Eye Hospital reported a revenue of 16.302 billion yuan for the third quarter of 2024, a year-on-year increase of 1.58%, and a net profit of 3.452 billion yuan, up 8.50%, with a gross profit margin of 51.02% [1]